The injection of CD34+ stem cells into newborn or young mice, also known as the Hu-SRC-SCID model, allows for the differentiation and development of a more complete immune system, including T cells, B cells, and innate immune cells; this model provided a more physiologically relevant tumor microenvironment, mimicking the interaction between immune cells and tumor cells in vivo (31, 32). The gene discussed is CD34; the disease is neoplasm.